Business
Jaguar Health Submits Abstract for First-of-Kind Study Evaluating the Impact of Diarrhea from Cancer Therapies in Breast Cancer Patients Who Received Placebo in its OnTarget Phase 3 Trial
SAN FRANCISCO, CA / ACCESSWIRE / October 8, 2024 / Jaguar Health, Inc.(NASDAQ:JAGX) ("Jaguar") today announced that a late-breaking abstract evaluating the
About this update from Jaguar Health, Inc.
[{"type":"text","content":"SAN FRANCISCO, CA / ACCESSWIRE / October 8, 2024 / Jaguar Health, Inc.(NASDAQ:JAGX) (\"Jaguar\") today announced that a late-breaking abstract evaluating the incidence, severity and management of diarrhea from targeted therapies with or without standard chemotherapy in the cohort of adult patients with breast cancer in the placebo group of the OnTarget phase 3 study recently conducted by Jaguar family company Napo Pharmaceuticals, was submitted by the study's primary investigators to a relevant oncology conference for consideration for a presentation. In this study 142 patients with solid tumors received placebo tablets and nearly 75 of them were patients with breast cancer receiving targeted therapies with or without standard chemotherapy. These findings were collected from patient reported outcomes (PROs) provided by the patients using digital applications for their gastrointestinal signs and symptoms.Napo is continuing the analysis of data from the OnTarget trial, with plans for further discussions with the FDA. The natural history from the placebo group of patients with breast cancer provides further insights into cancer therapy dose modifications necessitated due to cancer therapy-related diarrhea (CTD).\"To our knowledge, this is the first time that the natural history of gastrointestinal symptoms including diarrhea, abdominal pain and discomfort, urgency and fecal incontinence from targeted therapies and/or chemotherapy have been reported directly by patients either at the time of the events or on a daily or weekly basis throughout the treatment period of a cancer therapy-related diarrhea study,\" said Lisa Conte, Jaguar's president and CEO. \"Real world experience from PRO is different from the incidence of adverse effects reported by investigators in the package inserts. Side effects are never a tolerable toxicity, and we continue to remain focused on patient-centric studies to provide appropriate supportive care for adult patients with solid tumors to allow them to perform activities of daily living.\"About the Jaguar Health Family of CompaniesJaguar Health, Inc. (Jaguar) is a commercial stage pharmaceuticals company focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress, specifically associated with over...